BioArctic二季度Leqembi权利金增长和礼来合作未抵消近端亏损压力

Oil prices slide over 2% amid hopes for progress in Mideast diplomacy
Introduction & Market Context
BioArctic AB (publ) presented its second quarter 2026 financial results on August 26, 2026, highlighting significant strategic progress despite a modest operating loss in the quarter. The Swedish neurology-focused biotech company reported continued growth in Leqembi royalties, secured a landmark partnership with Eli Lilly, and expanded its pipeline into oncology, even as rising research and development costs pressured near-term profitability.
The company’s shares fell 4.93% to $328 following the presentation, down from a previous close of $345, as investors weighed the operating loss against longer-term strategic advances. At current levels, the stock trades below its 52-week high of $364.40 but remains well above the 52-week low of $257.
Financial Performance Highlights
BioArctic reported net revenues of SEK 248 million in the second quarter, unchanged from the prior-year period but reflecting a fundamentally different revenue composition. The prior-year quarter included a one-time SEK 223 million milestone payment from Eisai, while Q2 2026 was driven primarily by recurring royalties and collaboration income.
The company’s revenue mix is shifting toward sustainability, with recurring revenue now approaching SEK 200 million per quarter. Leqembi royalties reached SEK 179.4 million, representing a 12% increase from the first quarter and a 27% year-over-year gain. The company also recognized SEK 51 million from a Novartis upfront payment during the quarter.
As illustrated in the following quarterly financial performance overview, BioArctic reported an operating loss of SEK 6 million in Q2 2026, compared to a profit of SEK 179 million in the prior-year period. Operating expenses increased to SEK 232 million from SEK 193 million, driven primarily by research and development investments that now account for 75% of underlying operating costs.
The company’s cash position remained robust at SEK 2.0 billion at the end of June, rising to more than SEK 2.3 billion after receiving a $30 million upfront payment from Eli Lilly in July. BioArctic paid a dividend of SEK 177 million, or SEK 2 per share, in June.
The following chart details the company’s financial position and cash flow dynamics through the second quarter:
Management emphasized that despite the quarterly loss, the company expects to remain profitable for the full year 2026. Operating costs are projected to increase 40% to 60% from 2025 levels, though management indicated the increase would likely land near the low end of that range.
Leqembi Commercial Progress
The company’s presentation highlighted steady commercial momentum for Leqembi, the Alzheimer’s disease treatment developed in partnership with Eisai. Global sales of the drug reached ¥29.3 billion (approximately $184 million) in Q2 2026, up 12% from the first quarter and 27% year-over-year.
Regional performance varied significantly. U.S. sales totaled ¥15.5 billion (~$97 million), growing 13% sequentially as the market responded to simplified diagnostic pathways. China sales increased 17% quarter-over-quarter to ¥4.8 billion (~$30 million), with broader insurance coverage expected beginning in Q4 2026. However, Japan sales declined 6% to ¥6.1 billion (~$38 million), reflecting flat quarter-over-quarter performance.
The following chart illustrates BioArctic’s royalty trajectory and regional sales breakdown:
A significant milestone came with the FDA’s July 13, 2026 approval of Iqlik, a subcutaneous autoinjector formulation for initiation treatment. The product launched in the U.S. in August, offering patients the convenience of home administration rather than requiring visits to infusion centers. Japan approval for the subcutaneous version is expected in Q3 2026, with reimbursement anticipated in Q4 2026. China filed for approval in January 2026, with a decision expected in the first half of 2027.
The presentation detailed the global rollout strategy and market access progress across key regions:
Real-world evidence from the LEADER study presented at the Alzheimer’s Association International Conference (AAIC) in 2026 provided additional commercial validation. Among 432 patients across 13 U.S. clinical practices, 82.5% were stable or improved, and 78.9% of those treated for more than 18 months transitioned to maintenance treatment and remained on therapy. Importantly, severe ARIA-E (amyloid-related imaging abnormalities-edema) occurred in only 0.2% of patients, well below rates seen in clinical trials.
Looking ahead, Eisai is guiding for full-year Leqembi sales of ¥143.5 billion (approximately $910 million), representing 63% growth from fiscal year 2025. This forecast corresponds to approximately SEK 880 million in royalties for BioArctic over the 12-month period from Q2 2026 to Q1 2027.
Strategic Partnerships and Platform Validation
BioArctic’s presentation emphasized the company’s expanding partnership portfolio, which now represents more than $3 billion in potential milestone payments. The company secured two new strategic collaborations during the quarter, validating both its antibody expertise and its proprietary BrainTransporter™ technology platform.
The landmark agreement with Eli Lilly, announced during the quarter, carries a total value of up to $800 million plus royalties, with $770 million in milestones remaining. Under the terms, BioArctic will generate a new drug candidate by combining its BrainTransporter platform with a Lilly molecule targeting neurodegeneration. Lilly will assume full responsibility for global development and commercialization.
The company also announced a collaboration with Mesenkia Therapeutics focused on glioblastoma, marking BioArctic’s first expansion into oncology. BioArctic will produce a novel BrainTransporter-based drug candidate targeting HVEM, a protein found on certain glioblastoma tumor cells, and conduct preclinical proof-of-concept studies.
The following overview illustrates how these partnerships validate BioArctic’s core technology platforms:
BioArctic’s total partnership portfolio now includes agreements with five major pharmaceutical companies, as detailed in the presentation:
Chief R&D Officer Johanna Fälting characterized the Lilly agreement as significant external validation: "Lilly’s selection of the BrainTransporter for next generation CNS therapies provide a strong validation from a leading pharmaceutical company."
The BrainTransporter platform, which enables delivery of biotherapeutics across the blood-brain barrier, is being developed to accommodate multiple drug modalities including antibodies, enzymes, proteins, peptides, genetic medicines, and small molecules.
Pipeline Advancement
The presentation detailed progress across BioArctic’s expanding research and development pipeline, which now spans multiple neurodegenerative diseases and includes the company’s first oncology program.
Exidavnemab, an antibody targeting alpha-synuclein for Parkinson’s disease and Multiple System Atrophy, completed its phase 2a safety review. The EXIST study confirmed a favorable safety profile, providing a foundation for planning phase 2b studies in MSA and Parkinson’s disease-related dementia, expected to initiate in the first half of 2027.
BAN2238, a BrainTransporter-coupled alpha-synuclein antibody, is advancing through IND-enabling activities with clinical development planned for 2027. The program represents BioArctic’s strategy of developing complementary approaches that may serve different disease settings.
The following diagram illustrates the mechanism of action for BioArctic’s alpha-synuclein portfolio:
The company’s comprehensive pipeline now includes 20 programs across multiple therapeutic areas, as shown in the detailed overview below:
Management emphasized that the expanded portfolio is driving the increase in operating expenses. Research and development now accounts for 75% of underlying operating costs, reflecting the company’s investment in advancing multiple candidates toward clinical development.
Strategic Vision and 2030 Ambitions
BioArctic positioned the quarter’s achievements within the context of its ambition to become "Sweden’s next major biopharma company" by 2030. The presentation outlined progress across four strategic pillars: Leqembi commercialization, pipeline expansion, strategic partnerships, and financial strength.
CEO Gunilla Osswald emphasized the company’s dual leadership position: "We are among world leaders in two different areas," referring to the company’s highly selective antibody platform and its BrainTransporter technology.
Chief Commercial Officer Anna Grönblad highlighted upcoming catalysts for Leqembi growth, noting that Medicare Part D coverage beginning in January 2027 "will clearly be a commercial game changer" for U.S. market penetration.
Forward-Looking Catalysts
The company outlined a robust pipeline of near-term catalysts extending through mid-2027, including regulatory approvals, clinical data readouts, and potential partnership milestones.
Key upcoming events include:
- Potential Japanese approval for Leqembi subcutaneous initiation treatment in Q3 2026
- Japanese reimbursement approval expected in Q4 2026
- Full phase 2a results for exidavnemab in late 2026
- Potential Chinese approval for Leqembi subcutaneous formulation in H1 2027
- Initiation of exidavnemab phase 2b studies in H1 2027
- New data from the LEADER real-world study at the CTAD conference in November 2026
The presentation concluded with four key takeaways emphasizing the company’s progress:
Management reiterated that BioArctic’s strong cash position of SEK 2 billion, combined with growing recurring revenues from Leqembi royalties and multiple partnership upfront payments, provides a solid foundation for advancing its expanded pipeline while maintaining profitability for the full year 2026.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.